Every year, millions of infants are infected by a little-known virus that is the most common cause of respiratory disease in children. Respiratory syncytial virus (RSV) (Fig. 1) causes a spectrum ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

New phase 2b/3 trial results with MSD's experimental respiratory syncytial virus (RSV) antibody clesrovimab have fired a shot across the bows of AstraZeneca and Sanofi, currently predicting ...

In a recent study of a population of infants, published online May 6 in Pediatrics, 72% of infants were found to be immunized against respiratory syncytial virus (RSV). Nirsevimab administration ...

01. A committee of independent vaccine experts voted Wednesday to recommend lowering the age at which adults can get a vaccine against respiratory syncytial virus, potentially opening up access to ...

A study presented at ESCMID Global 2025 has revealed that adults with respiratory syncytial virus-associated acute respiratory infection (RSV-ARI) face a 2.7-fold higher risk of death within one ...

The panel will vote on April 16 about recommendations for three vaccines, including for respiratory syncytial virus and chikungunya, a mosquito-borne disease. The meeting of the Advisory Committee ...

This includes ABRYSVO ® (Respiratory Syncytial Virus Vaccine), which in October 2024, the U.S. Food and Drug Administration approved for the prevention of RSV-associated LRTD in adults aged 18 to ...

A study reveals that Respiratory Syncytial Virus-associated Acute Respiratory Infection increases death risk in adults. The risk is three times higher within a year. RSV can lead to ...